Methods of reducing mammographic breast density and/or breast cancer risk
The present disclosure is directed to generally methods and/or compositions for treating mammographic breast density and/or breast stiffness in a patient in need thereof, such as a pre-menopausal, a peri-menopausal or a post-menopausal patient, comprising the administration of an effective amount of androgenic agent and an effective amount of an aromatase inhibitor. The present disclosure is also directed to methods and/or compositions for reducing breast pain. The present disclosure is also directed to method and/or compositions for reducing elasticity and/or decreasing mechano-transduction on the genome of breast cells. The present disclosure is also directed to methods and/or compositions for stabilizing and/or increasing the levels of androgen receptor expression in breast tissue.
1. A method of reducing breast density in a patient in need thereof, comprising administering to the patient:
i) an effective amount of androgenic agent selected from the group consisting of testosterone, methyltestosterone, testosterone undecanoate, testosterone propionate, testosterone cypionate, and testosterone enanthate; and
ii) an effective amount of an aromatase inhibitor selected from the group consisting of: exemestane, formestane, anastrozole, letrozole, vorozole, and fadrozole;
wherein the method mitigates the treated patient's risk of developing breast cancer.
2. The method of claim 1 , wherein the effective amount of androgenic agent is testosterone and the effective amount of the aromatase inhibitor is anastrozole and is administered by subcutaneous implant.
3. The method of claim 1 , wherein:
i) the effective amount of the testosterone is 2-200 mg; and
ii) the effective amount of the anastrozole is 0.5-10 mg.
4. The method of claim 3 , wherein:
i) the effective amount of the testosterone is 2-200 mg; and
ii) the effective amount of the anastrozole is 0.5-10 mg.
5. The method of claim 4 , wherein the method improves breast compression during mammographic visualization or detection of the breast between one or more annual intervening mammographic detections.
6. The method of claim 4 , wherein the method stabilizes and/or increases levels of androgen receptor expression in breast tissue in at least one of the patient's breasts between one or more annual intervening mammographic detections.
7. The method of claim 4 , wherein the patient is pre-menopausal.
8. The method of claim 4 , wherein the patient is peri-menopausal.
9. The method of claim 4 , wherein the patient has, or is diagnosed with having, a breast with an area breast density percentage (ABD %) of 7.5% or greater.
10. The method of claim 9 , wherein the method reduces the ABD % or an absolute area breast density (AABD) of the patient's breast by at least 2% over a 2 week, 1 month, 2 month, 3 month, 6 month, 9 month, or 1 year period.
11. The method of claim 4 , wherein the patient has, or is diagnosed with having, a breast with a volume breast density percentage (VBD %) of 7.5% or greater.
12. The method of claim 11 , wherein the method reduces the VBD % or an absolute volume breast density (AVBD) of the patient's breast by at least 2% over a 2 week, 1 month, 2 month, 3 month, 6 month, 9 month, or 1 year period.
13. The method of claim 1 , wherein the method improves breast compression during mammographic visualization or detection of the breast between one or more annual intervening mammographic detections.
14. The method of claim 1 , wherein the method stabilizes and/or increases levels of androgen receptor expression in breast tissue in at least one of the patient's breasts between one or more annual intervening mammographic detections.
15. The method of claim 1 , wherein the patient is pre-menopausal.
16. The method of claim 1 , wherein the patient is peri-menopausal.
17. The method of claim 1 , wherein the patient has, or is diagnosed with having, a breast with an area breast density percentage (ABD %) of 7.5% or greater.
18. The method of claim 17 , wherein the method reduces the ABD % or an absolute area breast density (AABD) of the patient's breast by at least 2% over a 2 week, 1 month, 2 month, 3 month, 6 month, 9 month, or 1 year period.
19. The method of claim 1 , wherein the patient has, or is diagnosed with having, a breast with a volume breast density percentage (VBD %) of 7.5% or greater.
20. The method of claim 19 , wherein the method reduces the VBD % or an absolute volume breast density (AVBD) of the patient's breast by at least 2% over a 2 week, 1 month, 2 month, 3 month, 6 month, 9 month, or 1 year period.